



## Drug Design Targeting Phosphodiesterase

Guest Editor:

**Dr. Yinuo Wu**

School of Pharmaceutical  
Sciences, Sun Yat-Sen University,  
Guangzhou 510006, China

Deadline for manuscript  
submissions:

**25 August 2024**

### Message from the Guest Editor

Phosphodiesterases (PDEs) are a superfamily of enzymes that specifically hydrolyze the second messenger cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which can in turn be divided into PDE1-PDE11 subfamilies. At present, more than ten PDE inhibitors are available on the market, including heavy bomb PDE5 inhibitors sildenafil and tadalafil, as well as the PDE4 inhibitor Apremilast. On the other hand, PDE has been demonstrated to be the potential target for various diseases such as heart failure and neurodegenerative diseases. More and more inhibitors are being developed to target different PDE subtypes, which will greatly promote the emergence of new targets for second messenger-related diseases. This SI seeks to solicit research on the development of PDE inhibitors, as well as research related to the application of targeted PDE and chemical probes. Our aim is to provide a platform for discussing the latest research on PDE inhibitors and promoting the application of PDE inhibitors.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)